PubRank

Takashi Kobunai

Author PubWeight™ 24.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin Transl Oncol 2011 1.52
2 Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res 2006 1.32
3 Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J Clin Oncol 2012 1.17
4 Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 2011 1.08
5 Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 2011 1.06
6 Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today 2012 1.02
7 Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res 2007 1.01
8 Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochem Biophys Res Commun 2007 0.92
9 Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun 2007 0.91
10 Gene expression signature and the prediction of lymph node metastasis in colorectal cancer by DNA microarray. Dis Colon Rectum 2009 0.91
11 Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Dis Colon Rectum 2014 0.88
12 Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis. Clin Colorectal Cancer 2011 0.88
13 Gene expression signature for recurrence in stage III colorectal cancers. Cancer 2009 0.88
14 Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today 2012 0.87
15 Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. Eur J Cancer 2010 0.86
16 Gene expression of mesenchyme forkhead 1 (FOXC2) significantly correlates with the degree of lymph node metastasis in colorectal cancer. Int Surg 2012 0.85
17 DNA methylation and sensitivity to antimetabolites in cancer cell lines. Oncol Rep 2008 0.84
18 Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis Colon Rectum 2011 0.81
19 RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol 2011 0.79
20 Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo. Anticancer Res 2012 0.78
21 Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice. Exp Ther Med 2012 0.77
22 hRFI overexpressed in HCT116 cells modulates Bcl-2 family proteins when treated with 5-fluorouracil. Oncol Rep 2006 0.76
23 Lateral pelvic lymph node dissection or chemoradiotherapy: which is the procedure of choice to reduce local recurrence rate in lower rectal cancer? Ann Surg 2008 0.76
24 Prognostic significance of 18q loss of heterzygosity in microsatellite-stable colorectal cancer. J Clin Oncol 2010 0.76
25 Letter to the editor: genetic instability in the downregulation of sFRP1. Anat Rec (Hoboken) 2011 0.75
26 Survival in microsatellite-unstable colorectal cancer. Clin Cancer Res 2008 0.75
27 Does a cost-effective approach for the determination of KRAS mutations maximize the patient's benefit in a clinical setting? Pharmacogenomics 2011 0.75
28 Effect of cystathionine beta-synthase variant 844ins68bp and methylenetetrahydrofolate reductase A1298C polymorphisms in xenografts on 5-FU efficacy and doubling time. Cancer Lett 2005 0.75